The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Egrifta (Tesamorelin Acetate) Market Projected To Expand During 2026–2030?
During the historic period, growth was propelled by the increasing incidence of HIV-associated lipodystrophy, side effects arising from long-term antiretroviral therapy, the clinical validation of GHRH analogs, a heightened awareness of visceral fat risks, and an unmet demand for targeted abdominal fat reduction.
Anticipated growth during the forecast period is propelled by advancements in personalized HIV care, an expanding pipeline for peptide therapeutics, a rise in the diagnosis of metabolic complications, favorable reimbursement policies for specialty drugs, and an increased focus on the long-term quality of life for HIV patients.
Key trends observed in the forecast period encompass the development of long-acting peptide therapies, tailored treatments for lipodystrophy, the broadening of metabolic indications, the introduction of patient-centric injectable therapies, and a greater adoption of specialty biologic drugs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp
Which Strategic Drivers Are Supporting The Egrifta (Tesamorelin Acetate) Market Development?
A notable driver for the future expansion of the egrifta (tesamorelin acetate) market is the growing incidence of human immunodeficiency virus (HIV) cases. HIV cases denote instances where individuals become infected with HIV, progressively impairing their immune system. This increase in HIV can be partly attributed to inadequate awareness and educational efforts regarding preventive actions like condom usage and consistent testing, especially among demographics at higher risk. Egrifta promotes the secretion of growth hormone, which aids in reducing surplus visceral fat and enhancing body composition, thereby improving the general health and life quality of those living with HIV. As an illustration, in May 2024, data from the Minnesota Department of Health, a US-based state health agency, indicated that MDH documented 324 new HIV diagnoses in 2023, representing a 24% increase compared to 2022. Consequently, the expanding occurrence of human immunodeficiency virus (HIV) cases is propelling the growth of the egrifta (tesamorelin acetate) market.
What Key Segment Areas Are Included In The Egrifta (Tesamorelin Acetate) Market Assessment?
The egrifta (tesamorelin acetate) market covered in this report is segmented –
1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By End-Users: Hospitals, Specialized Clinics, Home Care
Which Trends Are Affecting The Egrifta (Tesamorelin Acetate) Market Framework?
The primary direction in the egrifta (tesamorelin acetate) market involves the creation of sophisticated synthetic peptide drugs, aiming to improve the efficacy of therapies for HIV-related lipodystrophy. These synthetic peptide drugs are engineered compounds designed to provide particular therapeutic outcomes by either imitating or amplifying the functions of natural peptides. For example, in December 2024, Theratechnologies Inc., a biopharmaceutical firm located in Canada, disclosed that the manufacturing of EGRIFTA SV had restarted after its contract manufacturer’s facility voluntarily ceased operations due to observations from an FDA inspection. One recently produced batch has passed quality control checks and awaits release pending approval of a prior approval supplement by the US Food and Drug Administration (FDA), with two more batches currently being produced. The company is actively managing its stock to satisfy patient needs through mid-January 2025 and is collaborating with the FDA to avert any potential shortage during 2025. EGRIFTA SV is exclusively distributed within the United States.
Which Companies Are Engaged In The Egrifta (Tesamorelin Acetate) Market Environment?
Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.
Access The Complete Egrifta (Tesamorelin Acetate) Market Report:
https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report
Which Region Accounts For The Highest Share Of The Egrifta (Tesamorelin Acetate) Market?
North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model